The purpose of this study is to look at a standardized methadone-based enhanced recovery after surgery protocol following pediatric cardiac surgery. This study will consist of randomly assigning children to receive the methadone-based recovery procedures or to receive current standard of care recovery procedures. Randomly assigning means that there is a 50/50 chance, like a coin flip, of being assigned to either research group.

Start Date01 Sep 2025

Sponsor / Collaborator

University of Pittsburgh

NCT06877858

/ Not yet recruitingPhase 1IIT

A Dose-Finding Study of Methadone Loading Dose Initiation for Opioid Use Disorder with Fentanyl Use

The goal of this proposal is to develop a "loading dose" approach to starting methadone to treat fentanyl opioid use disorder (OUD). We aim to conduct an assessor-blinded dose-finding study of 24 participants with fentanyl OUD recruited to a research unit for monitored methadone dosing. Participants will be randomized to standard methadone initiation vs. one of three loading dose approaches. The primary goal is to identify the maximum tolerated methadone loading dose appropriate for future study.

Start Date01 Sep 2025

Sponsor / Collaborator

University of Pennsylvania

NCT06940570

/ Not yet recruitingPhase 3IIT

A Randomized Single Center Trial to Determine the Efficacy of Methadone as a First Line Agent in the Reduction and Treatment of Pain in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation

Mucositis is a normal side effect of stem cell transplant which happens as a result of chemotherapy being given prior to a new donor cell infusion (bone marrow transplant). The chemotherapy will kill cancer cells, but good cells, such as those in the mouth, are killed too. The mouth cells going away causes the areas in the mouth to be blistered, irritated, sore, and extremely painful. Pain medication (usually morphine or hydromorphone if allergic to morphine) are given when oral blisters are seen or felt by patient in patient's mouth. However, one pain medication given through a vein in the patient may or may not be effective and providers are often challenged with providing good pain control while waiting for the new donor cells to grow, which will then heal the mouth. This is a period of waiting that is 6-8 weeks.
The investigators know that methadone, a second pain medication, may decrease pain in a different way than morphine. This is because methadone works in a different way in the brain than morphine. By giving these pain medicines together, the hope of the study is to show decreased pain while waiting for new cells to grow.
The goal of this clinical trial is to hope to learn whether adding methadone (second pain medication) to the current pain medication which is morphine alone (all patients will receive this pain medication) will help reduce the pain experience of participant. Current treatment of morphine alone is sometimes not entirely effective and so any improvement of pain while waiting for new cells to grow is one of the goals of this study. If methadone is effective in decreasing pain, then patients may benefit in the future from using these two medications up front when getting a transplant.
Participant in this study between 6-18 years of age and is needing a stem cell transplant for a disease that can potentially be cured by transplantation.
Participant in this study is receiving chemotherapy and/or radiation conditioning that can cause mucositis. Participants are being asked to participate in this study because participants meet criteria to receive methadone that may or may not reduce pain experience versus just being given morphine alone, which is what all patients are given when the participants have mucositis.
The main goal of the study is to see if less opioid (pain medication) when methadone is added in comparison to participant who uses PCA only. The investigators also want to learn if patient's overall function is improved if given methadone. Another goal would be to see the number of TPN days the participant received and if the participant who was given methadone began to eat sooner. Other smaller goals include learning about side effects of methadone, and if the hospital stay is less for those who receive the study medication.
This medication will be given at Children's Medical Center of Dallas while participant is admitted for the stem cell transplant. There is no sponsor that is funding the study and this drug will be given free of charge in exchange for participation in the study

Start Date01 Aug 2025

Sponsor / Collaborator

The University of Texas Southwestern Medical Center

100 Clinical Results associated with Methadone Hydrochloride

100 Translational Medicine associated with Methadone Hydrochloride

100 Patents (Medical) associated with Methadone Hydrochloride

20,368

Literatures (Medical) associated with Methadone Hydrochloride

31 Dec 2025·VETERINARY QUARTERLY

Perioperative drug management in non-critical companion animals: a retrospective study at a Spanish veterinary teaching hospital (2018–2022)

Article

Author: Susperregui, Julen ; Altónaga, José R. ; López, Cristina ; de la Puente, Raúl ; Rodríguez, José M. ; Díez, Raquel ; Vázquez, Milena ; Romero, Beatriz ; Sahagún, Ana M.

There is little information in veterinary literature on the perioperative pharmacological management of small animal patients, despite the existence of common protocols and the importance of properly managing this period to reduce anaesthesia-related detrimental effects. This study aimed to analyse the current use of perioperative drugs in companion animals treated at the Veterinary Teaching Hospital of the University of León (HVULE) in Spain over a period of 5 years (2018-2022), describe the prescription patterns of these medicines, and identify the main variables associated with their prescription to explore possible strategies to promote their appropriateness. A total of 3438 cases were included in this study. The animals that most frequently underwent surgery were dogs (58.2%), females (57.0%), and adults (73.0%). The primary procedures performed were reproductive (56.6%) and traumatological (19.8%) surgeries. Regarding pharmacological treatments, more than half (62.3%) belonged to the ATCvet classification QN group (nervous system), and the most common compounds were isoflurane (13.5%), methadone (13.5%), and propofol (12.7%). Amoxicillin/clavulanic acid (3.7%) and marbofloxacin (2.8%) (categories C and B in the European Medicines Agency categorisation, respectively) were the most prescribed antibiotics. These findings provide detailed data to help veterinary policymakers improve drug use during surgical procedures.

31 Dec 2025·Human Vaccines & Immunotherapeutics

Immunogenicity persistence after four intramuscular triple-dose or standard-dose hepatitis B vaccine in patients receiving methadone maintenance treatment: A 1-year follow-up study in China

Article

Author: Liang, Xiaofeng ; Wang, Fuzhen ; Xue, Tongchuan ; Yao, Tian ; Men, Zhaoyue ; Mo, Xinyuan ; Liu, Yuan ; Feng, Yongliang ; Wang, Suping ; Gao, Linying ; Wang, Keke ; Yuan, Yuan ; Gao, Yizhuo

CLINICAL TRIAL REGISTRATION:

ClinicalTrials.gov (NCT03962816).https://clinicaltrials.gov/ct2/show/NCT03962816.

01 Dec 2025·European Journal of Trauma and Emergency Surgery

Pre-injury narcotic drug use in isolated severe traumatic brain injury: effect on outcomes

Article

Author: Demetriades, Demetrios ; Jakob, Dominik Andreas ; Takahashi, Kyosuke ; Yamaguchi, Keishi ; Matsushima, Kazuhide ; Abe, Takeru

PURPOSE:

The aim of this study was to explore the association between pre-injury narcotic drug use (opioids, methadone, and/or oxycodone) and outcomes in isolated severe traumatic brain injury (TBI) patients.

METHODS:

ACS TQIP study included adult trauma patients (≥ 16 years) with complete drug and alcohol screening. Isolated severe TBI was defined as head trauma with AIS 3-5 and without significant extracranial trauma. Exact matching was used to compare patients with isolated pre-injury narcotic drug use to those with no illicit drug or alcohol use. Patients were matched 1:1 based on the following matching criteria: age, gender, mechanism of injury, Injury Severity Score, systolic blood pressure, head AIS, and comorbidities.

RESULTS:

Of 1,846,630 patients, 141,058 had isolated severe head injuries with complete drug and alcohol screenings. After exact matching, 1,560 patients in each group were analyzed. There were no significant differences in hospital mortality, craniectomy rates, complication rates, or length of hospital stay. Patients that tested positive for narcotics had lower rates of mechanical ventilation (16.5% vs. 25.3%, p < 0.01) and shorter ICU stays [3 (2-4) days vs. 3 (2-6) days; p < 0.01].

CONCLUSION:

Pre-injury narcotic drug use in isolated severe TBI is not associates with adverse outcomes. Further research is needed to understand the biochemical and physiological effects of narcotic drugs on TBI outcomes.

132

News (Medical) associated with Methadone Hydrochloride

18 Jul 2025

·www.einpresswire.com

New Opioid Use Disorder Treatment Hub Now Open in Bennington

For Immediate Release: July 18, 2025 Media Contact: Kyle Casteel - Media Lead Communication Office │ Department of Health 802-863-7280 │ [email protected] New Opioid Use Disorder Treatment Hub Now Open in Bennington Grand opening event planned for July 23 WATERBURY, VT — A new treatment hub for opioid use disorder is now open in Bennington, marking a significant expansion to the state's network of services for people recovering from substance misuse. The site is operated by BayMark Health Services – known as BAART Programs in Vermont – which is North America’s largest provider of medication-assisted treatment for substance use disorders. BAART Bennington began providing services in June and will celebrate a grand opening on July 23. “The opening of this facility is a testament to years of hard work and collaboration between the Health Department, BayMark, the Bennington community and many more partners,” said Health Department Deputy Commissioner Kelly Dougherty, who oversees the state’s substance use treatment programs. “By adding this new hub in Bennington to our statewide system of care, we are improving access and reducing barriers for Vermonters in recovery.” Vermont’s hub-and-spoke opioid treatment service system is organized through geographic regions—Northwest, Northeast, Central, Southeast, and Southwest. With the opening of BAART Bennington, each region now has at least one “hub,” a licensed Opioid Treatment Program with the authority to dispense buprenorphine and methadone, two powerful medications used to treat individuals with opioid use disorder. “Spokes” are healthcare practices that can provide office-based treatment supported with buprenorphine – previously the only level of care available in Bennington. “Before the Bennington hub opened, people seeking this level of treatment needed to travel significant distances, or outside of the state, to receive care,” Dougherty said. “Opioid misuse continues to impact our communities. Having accessible treatment for people in Vermont remains crucial.” The Health Department is supporting the new hub in Bennington with a $3.9 million grant to help cover startup, operational costs, and the cost of treatment for those without insurance through July 2026. BAART Bennington has an estimated capacity to serve about 400 people in need of medication to treat opioid use disorder annually, and offers other recovery services including case management, addiction and relapse prevention education, and referrals to community resources. Health officials said over 11,000 people received opioid treatment services from Vermont’s hub-and-spoke system of care in 2023. Grand Opening: Media are invited to BAART Bennington’s official grand opening at 120 Depot St, Ste 4 Bennington, VT 05201. The event is scheduled July 23 from 4 p.m. to 6 p.m. A ribbon-cutting ceremony will be followed by tours of the facility. Please RSVP with Sean Cossey at [email protected] by July 22. # # # About the Department of Health We have been the state's public health agency for more than 130 years, working every day to protect and promote the health of Vermonters. Visit HealthVermont.gov ─ Join us @HealthVermont on Facebook , Instagram , YouTube Translated Information – Print, video and audio resources are translated into many of the languages used in Vermont. Visit HealthVermont.gov/Translations for searchable tables of documents in each of the nine languages – including about preventing illness, healthy homes, and staying safe and healthy during extreme events like storms, power outages, hurricanes, and flooding. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

15 Jul 2025

·www.prnewswire.com

Navamedic ASA: Closing of the transaction to acquire the business of dne pharma

OSLO, Norway, July 15, 2025 /PRNewswire/ -- Reference is made to the stock exchange announcement published by Navamedic ASA ("Navamedic" or the "Company", OSE ticker: "NAVA") on 23 June 2025, regarding Navamedic entering into an asset purchase agreement for the acquisition of the business of dne pharma AS for a total consideration of up to NOK 225 million, whereby NOK 185 million is payable at closing, and the remaining NOK 40 million is payable in two tranches subject to achievement of certain agreed sales volumes for the acquired products (the "Transaction"). Navamedic is pleased to announce that the Transaction has today been successfully completed. The Acquisition encompasses dne pharma's business, including product portfolio, key employees and all essential contracts of the business, intellectual property, licenses, and distribution agreements. The product portfolio includes prominent products such as Ventizolve® (intranasal naloxone spray for opioid overdose reversal), Levopidon® (levomethadone), and Metadon Dne (methadone) for opioid substitution therapy. The acquired business will be integrated into Navamedic's existing commercial platform, enabling rapid market access and geographic expansion across the Nordics and selected European markets. "This acquisition represents a significant step in our strategic expansion into the rapidly growing field of addiction treatment and is well aligned with our long-term growth ambitions. Thanks to the strong collaboration among all parties involved, the transaction was completed in a smooth and efficient manner. We are pleased that the General Meeting unanimously approved the Rights Issue yesterday, and we are sincerely grateful for the continued support of Kistefos and the other underwriters," said Kathrine Gamborg Andreassen, CEO of Navamedic. The Acquisition is financed through a combination of new debt in the amount of NOK 110 million from Nordea Bank Abp, filial i Norge ("Nordea") and a rights issue approved at an extraordinary general meeting of Navamedic on 14 July (the "Rights Issue"). Navamedic has been assisted by DNB Carnegie a part of DNB Bank ASA ("DNB Carnegie") and Advokatfirmaet Thommessen ("Thommessen") in connection with the Acquisition, and Navamedic has been granted a bridge loan from Nordea enabling completion of the Acquisition before completion of the Rights Issue. Navamedic has retained DNB Carnegie, and Nordea Corporate Finance, a part of Nordea Bank Abp, filial i Norge as managers and Thommessen as legal advisors for the Rights Issue. "We are very pleased closing this transaction with Navamedic and we are confident that the Navamedic team will continue to grow the opioid substitution business developed by dne pharma, in particular the Ventizolve® products," says Geir Ove Engeset, CEO of dne pharma as. For further information, please contact: Lars Hjarrand, CFO, Mobile: +47 917 62 842 E-mail: [email protected], or Kathrine Gamborg Andreassen, CEO, Mobile: +47 951 78 880 E-mail: [email protected] About Navamedic Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's quality of life by being a reliable supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies. Our growing product portfolio has been carefully selected to meet current public health concerns, such as obesity, Parkinson's disease, and gastro-related ailments, to empower people to live healthier and more fulfilling lives. What sets us apart is our deep-rooted commitment to understanding the needs and requirements of the countries where we are present. Our local insight and competence enable us to understand the specific needs of each country where we operate and ultimately to gain market access. This makes us a preferred partner for international companies expanding their footprint across the Nordics and Benelux regions, through either in-licensing or out-licensing. Navamedic has been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo, Norway. For more information, please visit About dne pharma/Pharma Production Prior to closing of the Transaction, dne pharma was a Norwegian developer and distributor of addiction and pain therapies, including opioid substitution treatments and emergency overdose medications. dne pharma's wholly owned subsidiary, Pharma Production AS, will continue to manufacture and supply the product portfolio recently acquired by Navamedic, as well as concentrate on contract manufacturing and development services, including analytical services, supporting the long-term need for national pharmaceutical production capacity. . This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This information was brought to you by Cision WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Acquisition

11 Jul 2025

·www.fiercebiotech.com

Relmada terminates license agreement for troubled phase 3 depression asset

Relmada originally licensed esmethadone in 2018 for $180,000 upfront and subsequent payments of $45,000 every three months.\n After prematurely ending two phase 3 depression trials last year, Relmada Therapeutics has formally given up on the asset they were testing. The Florida-based biotech terminated its license agreement for esmethadone on July 7, with all of their obligations under the deal set to expire on Oct. 5.Relmada has tested esmethadone, which it called REL-1017, in several phase 3 trials for various major depressive disorder (MDD) indications. The prospect flopped in just about every one of them.In October 2022, REL-1017 failed to top placebo as an MDD monotherapy in the phase 3 RELIANCE III trial. Another stumble followed just months later, this time as an adjunctive MDD treatment in late-stage RELIANCE I, which the company attributed to “a limited number of high-enrolling sites with unplausible placebo response.”Esmethadone did better in a 2023 open-label trial, successfully improving depression symptoms, but the study had no placebo arm.The third phase 3 strike for REL-1017 came in December 2024, when Relmada revealed that its RELIANCE II trial, which was testing esmethadone as an adjunctive treatment for MDD, was unlikely to hit its primary endpoint. As a result, Relmada scrapped the trial and another related study, RELIGHT, which used a similar design, and announced plans to pursue strategic alternatives like a merger or sale of the company.Esmethadone is a component of methadone, the pain and substance use medication. Relmada originally licensed the candidate in January 2018 from Charles Inturrisi, Ph.D., and Paolo Manfredi, M.D., for an upfront fee of $180,000. Inturrisi, a pharmacologist at Cornell University, originally developed esmethadone and licensed it to Medeor, which Manfredi co-founded. Relmada merged with Medeor in 2013.Manfredi’s Medeor is not to be confused with kidney transplant company Medeor Therapeutics. As part of the licensing deal, Relmada was paying Inturrisi and Manfredi $45,000 every three months, a stipulation that was set to continue until esmethadone was sold as a commercial product or the patent on it expired.Relmada is now focused on making strategic asset acquisitions, according to its website, as well as advancing remaining assets NDV-01 and sepranolone. NDV-01 is currently being tested in an open-label phase 2 trial in non-muscle invasive bladder cancer, while sepranolone is a phase 2 Tourette syndrome asset that Relmada purchased in February from Asarina Pharma.

Phase 3Phase 2License out/inAcquisitionClinical Trial Termination

100 Deals associated with Methadone Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D02102	Methadone Hydrochloride	N07BC02	DB00333

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cancer Pain	Japan	Shionogi & Co., Ltd.	01 Mar 2013
Opioid-Related Disorders	China	Central Pharmaceutical JSC No. 3	01 Jan 1997
Opioid abuse	United States	Hikma Pharmaceuticals USA, Inc.	14 Mar 1973
psychological symptoms behavior compulsive behavior addiction	United States	Hikma Pharmaceuticals USA, Inc.	14 Mar 1973
psychological symptoms behavior compulsive behavior addiction	United States	SpecGx LLC	14 Mar 1973
Opium Dependence	United States	Mylan Institutional LLC	13 Aug 1947
Pain	United States	Mylan Institutional LLC	13 Aug 1947

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetic Neuropathies	Phase 2	-	Methapharm, Inc.	01 Jan 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04214834 (CTgov)	Phase 3	Neonatal Abstinence Syndrome	189	methadone+morphine (Rapid Wean)	tfoxnpdnzq(vafuhkvmpy) = jxadfknzsr uywlhrljlz (ahjiytpyyb, 6.3) View more	-	13 Mar 2025
				methadone+morphine (Slow Wean)	tfoxnpdnzq(vafuhkvmpy) = eqezzfxivc uywlhrljlz (ahjiytpyyb, 6.1) View more
NCT05425420 (MTH02, CTgov)	Phase 1/2	Pain, Postoperative	22	Methadone	wezgcdhtne(kkeivjwogw) = knhvcfofnp uscufcyakz (dayjwtrfml, 1.42) View more	-	10 Feb 2025
NCT05244226 (CTgov)	Phase 2	Sleep Apnea, Obstructive \| Tonsillitis \| Pain, Procedural	66	Hydromorphone+Fentanyl	zemkwkzvkp(kkqqeuspti) = fgdlcssmez xrviqyisio (vizranbzqr, wibrzrqecs - cjqfktarss) View more	-	17 Oct 2024
Pubmed \| Anesthesiology	Not Applicable	-	60	Methadone 0.1 mg/kg	wlawptgzbd(hplgwxkxag) = nwuleudbzo wpyzqmngmi (msqsraoogp, 0.1 - 1.4)	Positive	01 Sep 2024
				Methadone 0.15 mg/kg	wlawptgzbd(hplgwxkxag) = iclxmblrry wpyzqmngmi (msqsraoogp, 0 - 1.4)
Pubmed	Not Applicable	Opioid abuse	303	Buprenorphine	hcfmscswpt(hjismuydaa) = hqpesrtlaa femafwkood (gqjwrlzfyx ) View more	Positive	01 Jul 2024
				Methadone	hcfmscswpt(hjismuydaa) = hrrmsogaqj femafwkood (gqjwrlzfyx ) View more
NCT03033732 (Pubmed \| HIV Med)	Phase 4	Opioid abuse	272	Methadone	pjzzsdcavx(aacqfsgrnj) = efvsplczmf jkddqxxtij (xzuccrxrap ) View more	Positive	01 Jul 2024
				Buprenorphine/naloxone	pjzzsdcavx(aacqfsgrnj) = ifuylljatd jkddqxxtij (xzuccrxrap ) View more
ENDO2024	Not Applicable	Hyperinsulinism	-	Methadone	xhamzcbjkc(mquuxqqksx) = ctwzicyagz ujfrmncfeq (sqllnvewlr, 0.5 - 3.3) View more	-	01 Jun 2024
ENDO2024	Not Applicable	Kidney Failure, Chronic	-	Methadone 110 mg daily	bcdimoudsg(aywvvkuyft) = Methadone induced hypoglycemia okhjjefidg (omflxgebcv )	-	01 Jun 2024
NCT03033732 (Pubmed \| Can J Psychiatry) Manual	Phase 4	Opioid abuse	268	methadone or buprenorphine/naloxone	-	Negative	01 Mar 2024
				Methadone Maintenance Therapy (MMT)	oksjyjedqk(tdcafcedub) = aanjksqfdv ymikiotsze (qyqhrxqxpr ) View more
NCT02252432 (CTgov)	Phase 4	Pain, Postoperative	13	methadone+Ketamine (Ketamine)	xpjzuarutx(zqfvobmrpw) = tdqaixwzsq eigjzhbgjh (feekexwarj, 20) View more	-	29 Feb 2024
				methadone+ketamine (Methadone)	xpjzuarutx(zqfvobmrpw) = axetqckgbk eigjzhbgjh (feekexwarj, 16) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis